跳至主要内容
临床试验/NCT01246505
NCT01246505已完成3 期

Peripheral Facilitated Antegrade Steering Technique in Chronic Total Occlusions

BridgePoint Medical11 个研究点 分布在 1 个国家目标入组 105 人开始时间: 2011年7月1日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
105
试验地点
11
主要终点
Incidence of Patients with a Major Adverse Events (MAE)

研究概览

简要总结

Study of the BridgePoint Medical System in the crossing of chronic total occlusions of the lower extremities.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • suitable candidate for non-emergent, peripheral angioplasty
  • documented de-novo or restenotic peripheral CTO lesion with TIMI 0 flow for at least 90 days and satisfactory distal vessel visualization (collateral supply)
  • limb ischemia or claudication, Rutherford class I-III (grade 1-5) caused by the occluded artery

排除标准

  • intolerance to aspirin or a neutropenic response to Ticlopidine or Clopidogrel
  • appearance of thrombus or intraluminal filling defects
  • peripheral intervention in the target limb within two weeks of the procedure
  • renal insufficiency (serum creatinine of > 2.3 mg/dl)
  • contraindication to a peripheral artery intervention
  • participation in another investigational protocol

结局指标

主要结局

Incidence of Patients with a Major Adverse Events (MAE)

时间窗: 30 Day

MAE is defined as death, major unplanned amputation, perforation requiring intervention, or target lesion revascularization due to complication.

Incidence of Intraprocedural Technical Success

时间窗: Intraprocedural (<24 hours)

Technical success is defined as the placement of a guidewire in the true lumen distal to the CTO

次要结局

未报告次要终点

研究者

发起方
BridgePoint Medical
申办方类型
Industry
责任方
Sponsor

研究点 (11)

Loading locations...

相似试验